Ocuphire Pharma Inc. (OCUP)
1.17
-0.16 (-12.03%)
At close: Oct 23, 2024, 8:00 PM
-12.03% (1D)
| Bid | n/a |
| Market Cap | 31.74M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -0.54 |
| PE Ratio (ttm) | -2.1666666666666665 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | n/a |
| Volume | 675,971 |
| Avg. Volume (20D) | 139,151 |
| Open | 1.33 |
| Previous Close | 1.33 |
| Day's Range | 1.07 - 1.36 |
| 52-Week Range | 1.07 - 3.40 |
| Beta | 0.31 |
About OCUP
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induc...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 10, 2005
Employees 14
Stock Exchange NASDAQ
Ticker Symbol OCUP
Website https://www.ocuphire.com
Analyst Forecast
According to 2 analyst ratings, the average rating for OCUP stock is "Buy." The 12-month stock price forecast is $14, which is an increase of 1096.58% from the latest price.
Stock Forecasts6 months ago
+0%
Ocuphire Pharma shares are trading higher after th...
Unlock content with
Pro Subscription
8 months ago
-21.08%
Ocuphire Pharma shares are trading lower after the company reported worse-than-expected Q2 financial results.
